The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction |
| |
Authors: | Carsten Goessl Leonid Katz William C Dougall Paul J Kostenuik Holly Brenza Zoog Ada Braun Roger Dansey Rachel B Wagman |
| |
Institution: | Amgen Inc., Thousand Oaks, California. Amgen Inc., Seattle, Washington. |
| |
Abstract: | Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal-related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|